Research programme: pain therapeutics - Celtic Pharma

Drug Profile

Research programme: pain therapeutics - Celtic Pharma

Alternative Names: IDEA-077; TDT-077

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator IDEA
  • Developer Celtic Pharma
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Postherpetic neuralgia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in Bermuda (Topical, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in Bermuda (Topical, Gel)
  • 20 Jun 2008 Preclinical trials in Postherpetic neuralgia in Bermuda (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top